Connecticut Schedules Kratom: The 2026 Ban Explained

Connecticut's kratom ban arrived by the least typical route of 2026's three new prohibitions: not a standalone kratom bill, but a regulatory scheduling process set in motion by a broader drug-control law the previous summer. By spring 2026, kratom, 7-OH, and five other substances were Schedule I in Connecticut, and retailers had a hard removal deadline. Here is the full sequence.

The Legal Mechanism

The enabling statute is Public Act 25-101 — a Department of Consumer Protection drug-control and cannabis/hemp regulation act passed unanimously by both chambers and signed by Governor Ned Lamont in June 2025. Section 4 of the act did something unusual: rather than scheduling kratom directly, it required the Commissioner of Consumer Protection to designate seven named substances as controlled substances and classify each in the appropriate schedule: 7-hydroxymitragynine; Mitragyna speciosa (kratom) including its leaves, stem, and any extracts; bromazolam; flubromazolam; nitazenes; tianeptine; and phenibut.

The DCP's proposed regulation classified all seven as Schedule I, reasoning that controlled-substance schedules follow the DEA's framework, Schedule I covers substances with no accepted medical use and high abuse potential, and no federal or Connecticut medical use had been established for any of the seven. A public hearing in October 2025 drew hundreds of written and oral comments — including organized opposition asking for a less restrictive schedule for kratom — which the Department addressed in its December 2025 response before sending the regulation forward.

The 2026 Timeline

The DCP announced the scheduling with Connecticut described as the seventh state to designate kratom and its derivatives, including 7-OH, as Schedule I. Commissioner Bryan T. Cafferelli framed the action around unregulated availability — products sold to all ages at gas stations and smoke shops with no testing or protections — and committee members from both parties emphasized child access. The law does leave one door open that pure statutes usually don't: the DCP retains authority to reschedule the substances in the future if research establishes a beneficial medical purpose.

What It Means in Practice

• For Connecticut residents: kratom in every form — leaf, extract, gummy, beverage — is a Schedule I controlled substance. Possession, sale, and distribution are prohibited, including product purchased legally before the change.
• For retailers: the removal deadline passed March 25, 2026; DCP coordinated with sister agencies to educate local law enforcement on removal and enforcement.
• For travelers: Connecticut sits between New York and Rhode Island — both of which permit regulated kratom — making I-95 and I-84 corridors a three-state legality sandwich. Do not carry kratom into Connecticut.
• For online orders: compliant vendors block Connecticut addresses; this site does not solicit Connecticut orders.

As in Tennessee and Kansas, regular users affected by the change should not stop abruptly after sustained use without medical guidance — Connecticut's DCP coordinated with the Department of Mental Health and Addiction Services precisely because the agencies anticipated residents needing support as the scheduling took effect. That help is legal and confidential.

The Hearing Record: Opposition Heard, Not Followed

The regulatory route did include a genuine public process, and the record is instructive for advocates elsewhere. The October 2025 hearing and comment period drew over four hundred written and oral submissions, the large majority opposing Schedule I placement for kratom or asking for a less restrictive schedule — organized largely through the same consumer-advocacy channels that beat the DEA in 2016. The Department's formal response, posted in December 2025, conceded nothing on the merits but explained its constraint plainly: Public Act 25-101 gave the DCP no authority to leave the substances unscheduled, the Department conducts no independent drug research, controlled-substance schedules follow the DEA's framework, and with no established federal or Connecticut medical use, the evidence before it supported only Schedule I.

That reasoning is the strategic lesson of the Connecticut fight: once the legislature mandated scheduling, the comment battle was effectively over before it began — the only live question was which schedule, and the Department's own criteria answered it. Advocates who want a different outcome in mandate-style states have to win at the statute stage, not the regulation stage. The one durable concession is the rescheduling authority: unlike a statutory ban, Connecticut's framework lets the DCP revisit the classification if research establishes medical benefit, making it — on paper — the most reversible of the nine state prohibitions.

The Bigger Picture

Connecticut's route — legislature mandates, agency schedules, review committee approves — moved faster than most standalone bills and with less floor drama, which is why it caught parts of the industry by surprise despite eighteen months of public process. It also bundled kratom with substances like nitazenes and tianeptine ("gas station heroin" adjacents in much of the coverage), a framing choice that shaped the debate — nitazenes are synthetic opioids implicated in overdose deaths, and grouping a botanical leaf with them foreclosed any product-category distinction of the kind Ohio, Florida, and the DEA drew this same year. Advocates argued the bundle was the whole ballgame; once kratom shared a bill line with novel synthetic opioids, no legislator was going to carve it out. The counterargument — that unregulated gas-station availability to minors put all seven substances in the same public-health frame — carried the committee unanimously, twice. The result stands in sharp contrast to next-door Rhode Island, which completed the first-ever ban reversal the same spring under a regulated framework — the two states now bookend the entire American policy spectrum across one border (see our Rhode Island analysis). The full national picture is in the 2026 landscape guide.